Open AccessHiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
Author(s) -
David S. Fedson,
Steven M. Opal,
Ole Martin Rordam
Publication year - 2020
Publication title -
mbio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.562
H-Index - 121
eISSN - 2161-2129
pISSN - 2150-7511
DOI - 10.1128/mbio.00398-20
Subject(s) - ards , covid-19 , medicine , drug , disease , intensive care medicine , immunology , lung , virology , infectious disease (medical specialty) , pharmacology , outbreak
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.